|
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Metabolic Syndrome and Glucose Control Including Insulin
Test Code91398
CPT Codes
82947, 83525, 82465, 84478, 83718
Includes
Glucose
Insulin, Intact, LC/MS/MS
Cholesterol, Total
Triglycerides
HDL and Calculated Components
Insulin, Intact, LC/MS/MS
Cholesterol, Total
Triglycerides
HDL and Calculated Components
Preferred Specimen
3 mL serum collected in a Serum Separator Tube (SST®) and
0.4 mL serum collected in a red-top tube (no gel)
0.4 mL serum collected in a red-top tube (no gel)
Patient Preparation
See individual assays
Triglyceride test only: Patient should fast 9-12 hours prior to collection.
As part of lipid panel testing: A fasting sample is not required.
Minimum Volume
1.5 mL serum collected in an SST® and 0.2 mL serum collected in a red-top tube (no gel)
Instructions
The assay manufacturer Beckman Coulter advises: "N-Acetyl Cysteine (NAC), when administered in therapeutic concentrations (for the treatment of acetaminophen overdose), has been...determined to interfere with assays for... Cholesterol, Uric Acid" where "NAC interference may lead to falsely low results." According to Beckman Coulter, the NAC interference should be insignificant by 12 hours after completion of the initial loading dose of an IV infusion treatment regimen consisting of an initial loading dose of 150 mg/kg administered over 1 hour, a second dose of 50 mg/kg administered over 4 hours and a third dose of 100 mg/kg administered over 16 hours.
Transport Container
Plastic screw-cap vial (x2)
Transport Temperature
Frozen
Specimen Stability
Serum Separator Tube (SST®)
Room temperature: 48 hours
Refrigerated: 7 days
Frozen: 15 days
Red-top tube (no gel)
Room temperature: 24 hours
Refrigerated: 24 hours
Frozen: 28 days
Room temperature: 48 hours
Refrigerated: 7 days
Frozen: 15 days
Red-top tube (no gel)
Room temperature: 24 hours
Refrigerated: 24 hours
Frozen: 28 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis • Gross icteria • Moderate icteria • Anticoagulants
Methodology
Chromatography/Mass Spectrometry • Spectrophotometry (SP)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Mon, Wed, Fri nights; Report available: 3-6 days
Reference Range
See Laboratory Report
Clinical Significance
Identifying patients who have metabolic syndrome and who are thus at higher risk of diabetes, coronary heart disease or stroke. Identifying patients who are insulin resistant (fasting insulin at or above the 75th percentile) and who are thus at higher risk of diabetes, coronary heart disease, stroke, or liver disease. Monitoring of risk factors and insulin levels after life style change, medication use, or both.